Lozartan

Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation
Am J Physiol Renal Physiol 301:F580-F587, 2011. First published 8 June 2011; doi:10.1152/ajprenal.00042.2011 You might find this additional info useful... This article cites 28 articles, 14 of which can be accessed free at:http://ajprenal.physiology.org/content/301/3/F580.full.html#ref-list-1 Updated information and services including high resolution figures, can be found at: http://ajprenal.physiology.org/content/301/3/F580.full.html Additional material and information about AJP - Renal Physiology can be found at: http://www.the-aps.org/publications/ajprenal

C. Fanelli, B. H. V. Fernandes, F. G. Machado, C. Okabe, D. M. A. C.Malheiros, C. K. Fujihara and R. Zatz

Downloaded from ajprenal.physiology.org on November 22, 2011

This infomation is current as of November 22, 2011.

AJP - Renal Physiology publishes original manuscripts on a broad range of subjects relating to the kidney, urinary tract, and their respective cells and vasculature, as well as to the control of body fluid volume and composition. It is published12 times a year (monthly) by the American Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2011 by the American Physiological Society. ISSN: 0363-6127, ESSN: 1522-1466. Visit our website at http://www.the-aps.org/.

Am J Physiol Renal Physiol 301: F580–F587, 2011. First published June 8, 2011; doi:10.1152/ajprenal.00042.2011.

Effects of losartan, inmonotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation
C. Fanelli, B. H. V. Fernandes, F. G. Machado, C. Okabe, D. M. A. C. Malheiros, C. K. Fujihara, and R. Zatz
Laboratory of Renal Pathophysiology (LIM-16), Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
Submitted20 January 2011; accepted in final form 31 May 2011

Fanelli C, Fernandes BH, Machado FG, Okabe C, Malheiros DM, Fujihara CK, Zatz R. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. Am J Physiol Renal Physiol 301: F580 –F587, 2011. First published June 8, 2011;doi:10.1152/ajprenal.00042.2011.—We recently standardized a model (LLact) of severe chronic kidney disease based on impaired nephrogenesis by suppression of angiotensin II activity during lactation (Machado FG, Poppi EP, Fanelli C, Malheiros DM, Zatz R, Fujihara CK. Am J Physiol Renal Physiol 294: F1345–F1353, 2008). In this new study of the LLact model, we sought to gain further insight into renal injury mechanisms associatedwith this model and to verify whether the renoprotection obtained with the association of the angiotensin II receptor blocker losartan (L) and hydrochlorothiazide (H), which arrested renal injury in the remnant kidney model, would provide similar renoprotection. Twenty Munich-Wistar dams, each nursing six pups, were divided into control, untreated, and LLact groups, given losartan (L; 250 mg·kg1·day 1) until weaning. The male LLact offspring remained untreated until 7 mo of age, when renal functional and structural parameters were studied in 17 of them, used as pretreatment control (LLactPre), and followed no further. The remaining rats were then divided among groups LLact V, untreated; LLact L, given L (50 mg·kg 1·day 1) now as a therapy; LLact H, given H (6 mg·kg 1·day 1); and LLact LH,given L and H. All parameters were reassessed 3 mo later in these groups and in agematched controls. At this time, LLact rats exhibited hypertension, severe albuminuria, glomerular damage, marked interstitial expansion/inflammation, enhanced cell proliferation, myofibroblast infiltration, and creatinine retention. L monotherapy normalized albuminuria and prevented hypertension and the progression...